News | March 01, 2012

Cell>Point Licenses PET/SPECT Cardiac, Cancer Agent for Asia Pacific

March 1, 2012 — Cell>Point announced it entered into a licensing agreement for South Korea, Taiwan, Malaysia, Vietnam and the Philippines with Hyun Imc Co. Ltd., headquartered in Seoul, South Korea, for the kit manufacture, marketing and distribution of Cell>Point’s cancer and cardiology nuclear imaging product.

The product is based on its technetium-99m-labeled ethylenedicysteine-n-acetyl-glucosamine (99mTc-EC-G) radiotracer. Hyun Imc will be responsible for sponsoring clinical studies and seeking regulatory approval in each of the countries covered by the license. Cell>Point will receive an upfront payment, and development and regulatory milestone payments, as well as royalties on gross sales from Hyun Imc.

99mTc-EC-G, invented at the University of Texas MD Anderson Cancer Center and acquired by Cell>Point, is a target-specific molecular imaging radiopharmaceutical that has moved into a Phase 3 lung cancer imaging trial and Phase 2 cardiology imaging trial. It is injected intravenously and then imaged using a single photon emission computed tomography (SPECT) camera.

99mTc-EC-G Phase 3 lung cancer imaging trial

For the Phase 3 lung cancer study, all patients will be imaged on combination SPECT/CT (computerized tomography) and PET/CT cameras. Where combination cameras are not available, a special workstation will be used to integrate the patient images taken from the stand-alone SPECT or PET cameras, as the case may be. Using a workstation to integrate the images allows the medical site to take full advantage of 99mTc-EC-G without the need for a new combination SPECT/CT camera on the premises. This should significantly expand the utilization of the installed SPECT camera base in the United States and the rest of the world, which is already orders-of-magnitude greater than the PET camera base. The lung cancer trial will be followed by Phase 4 trials in lymphoma and breast, liver, colorectal, prostate, and head and neck cancers.

99mTc-EC-G Phase 2 cardiology imaging trial

In a separate clinical trial, 99mTc-EC-G has moved from a Phase 1b to a Phase 2 cardiovascular imaging study. The product is the same as that used in the oncology trials. 99mTc-EC-G exhibits very low uptake in the normal heart; however, it exhibits very high uptake in heart areas that have suffered ischemia (i.e., profound deprivation of blood flow), such as a myocardial infarction. The Phase 2 cardiovascular trial will involve patients who have suspected coronary artery disease and compare 99mTc-EC-G images of the heart with images obtained from a full “stress/rest” myocardial perfusion imaging (MPI) study.

It should be noted that one of the objectives of the study is to compare the results from the “rest” only portion of the 99mTc-EC-G study to the results from the full “stress/rest” MPI study. Based on clinical evidence from the previous Phase 1b study, Cell>Point believes clinical information learned from the 99mTc-EC-G “rest” study will be potentially greater than that of the full “stress/rest” MPI study, which uses 99mTc-sestamibi for the stress image and thallium-201 for the rest image and takes five to seven hours. If the “rest” only 99mTc-EC-G study yields as good as or greater clinical information compared to traditional MPI, then the 99mTc-EC-G rest study—which can be conducted in 30 to 45 minutes — should dramatically improve cardiovascular imaging.

For more information: www.cellpointweb.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init